Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
IPO Year:
Exchange: NYSE
Website: lilly.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/13/2024 | $1060.00 | Buy | Citigroup |
8/12/2024 | $1025.00 | Hold → Buy | Deutsche Bank |
2/21/2024 | $820.00 | Buy → Hold | DZ Bank |
2/16/2024 | $805.00 → $950.00 | Overweight | Morgan Stanley |
12/21/2023 | $660.00 → $610.00 | Buy → Outperform | Daiwa Securities |
11/9/2023 | $535.00 | Hold | Deutsche Bank |
10/20/2023 | $612.00 → $710.00 | Buy | UBS |
8/9/2023 | $408.00 → $615.00 | Hold → Buy | Jefferies |
7/26/2023 | $360.00 → $525.00 | Buy | Citigroup |
7/14/2023 | $560.00 | Buy | HSBC Securities |
3 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 11.36% on an annualized basis producing an average annual return of 23.33%. Currently, Eli Lilly and Co has a market capitalization of $730.31 billion. Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $23,116.69 today based on a price of $811.09 for LLY at the time of writing. Eli Lilly and Co's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automat
Investors have a strong opinion on Tesla Inc. (NASDAQ:TSLA) unlike other companies such as LVMH Moët Hennessy Louis Vuitton SE (OTC:LVMHF) or Eli Lilly and Co (NYSE:LLY), former Tesla Investor Relations head Martin Viecha said on Wednesday and company CEO Elon Musk agrees. What Happened: “One of the great things about speaking with investors about Tesla is that *everyone* has an opinion about this company, often a strong one,” Viecha wrote on X, formerly Twitter. People, however, do not have such strong opinions on Dior’s parent LVMH, or pharmaceutical company Eli Lilly known for its diabetes and clinical depression drugs, he added. Musk agreed to Viecha, with a short, “Yeah.” Y
Across the recent three months, 25 analysts have shared their insights on Eli Lilly and Co (NYSE:LLY), expressing a variety of opinions spanning from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 18 0 0 0 Last 30D 0 1 0 0 0 1M Ago 4 9 0 0 0 2M Ago 1 4 0 0 0 3M Ago 2 4 0 0 0 Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.
In Wednesday’s pre-market trading, shares of Novo Nordisk A/S (NYSE:NVO) are witnessing a fall after the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk’s semaglutide, Wegovy, to reduce the risk of heart complications or strokes in overweight and obese adults, What Happened: At the time of writing, Novo Nordisk was trading 1.25% lower at $131.61 in the pre-market after closing at $133.28 on Tuesday, according to Benzinga Pro. The weak pre-market performance can also be linked to increased competition in the weight loss drugs market. Last week, shares of Novo Nordisk and rival Eli Lilly (NYSE:LLY) dipped after Pfizer Inc. (NY
- Bloomberg
Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co (NYSE:LLY) revealed 15 unusual trades. Delving into the details, we found 26% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $881,458, and 10 were calls, valued at $903,584. Predicted Price Range After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $430.0 and $980.0 for Eli Lilly and Co, spanning the last three months. Volume & Open Interest Development In today's trading context, the average open interest fo
President Joe Biden‘s decision on Sunday to drop his bid for a second term in the White House was “yet another curveball for equity investors,” according to RBC Capital Markets analyst Lori Calvasina. So far this year, investors have exhibited “the same amount of discomfort in talking about the US election and its stock market/economic implications in our meetings that one might feel by staring at the sun for too long,” Calvasina wrote in a Monday analyst note. How the stock market will react to Biden’s historic decision “remains to be seen,” she adds. “The main thing we've been remembering,” Calvasina says, “is how so many of the US-based investors we've spoken with this year seeme
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics. AnaptysBio has a pipeline of checkpoint agonists, including rosnilimab, a PD-1 agonist in development for rheumatoid arthritis (RA) and ulcerative colitis (UC), and ANB032, a B and T cell lymphocyte attenuator (BTLA) agonist in development for atopic dermatitis (AD). In Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, inflammatory cytokine secretion and PD-1(high) T cells and demonstrated favorable safety. Related: Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Trigge
Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more than $23 billion since 2020 INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. This unique facility will give Lilly the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinica
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's. However, th
Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year study The safety profile at three years was consistent with the previously published two-year results INDIANAPOLIS, Sept. 25, 2024 /PRNewswire/ -- More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to EBGLYSS™ treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clea
Japan is the second major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024 INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE:LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology. Japan is the second major market in which Kisunla has been approved for use. In Japan, by 2030, the number of patie
EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks EBGLYSS delivers long-lasting efficacy for patients through one year of treatment with a monthly maintenance dose INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg)
Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. The company also unveiled its new $800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity tr
Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 1 diabetes who require daily basal and multiple daily mealtime insulin injections. The data were published in The Lancet and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024. In the trial, efsitora met the primary endpoint
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin naïve). The data were published in The New England Journal of Medicin
INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage
In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a second phase 3 study, QWINT-3, efsitora also delivered non-inferior A1C reduction compared to daily insulin in people with type 2 diabetes switching from daily basal injections INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using basal insulin for the first time (insulin naïve) and in those who
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
FWP - ELI LILLY & Co (0000059478) (Subject)
10-Q - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
11-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i
Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding the sale of rights for Baqsimi, non-incretin revenue increased 17% worldwide and 25% in the U.S.Q2 2024 EPS increased 68% to $3.28 on a reported basis and increased 86% to $3.92 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.2024 full-year revenue guidance raised by $3 billion; reported EPS guidance raised $2.05 to the range of $15.10 to $15.60, and non-GAAP EPS guidance raised $2.60 to the range of $16.10 to $16.60. Pipeline progress included approval of Kisunl
INDIANAPOLIS, July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About Lilly Lilly is a medicine company turning science into healing
INDIANAPOLIS, June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on Sept. 10, 2024, to shareholders of record at the close of business on Aug. 15, 2024. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discover
INDIANAPOLIS, May 6, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on June 10, 2024, to shareholders of record at the close of business on May 16, 2024. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discove
Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's disease in the U.S. and EU; resubmission of lebrikizumab for atopic dermatitis in the U.S.; and initiation of lepodisiran in a Phase 3 study for atherosclerotic cardiovascular disease.Q1 2024 EPS increased 66% to $2.48 on a reported basis and increased 59% to $2.58 on a non-GAAP basis, both inclusive of $0.10 of acquired IPR&D charges.2024 full-year revenue guidance raised by $2.0 billion; reported EPS guidance raised $1.25 to be in the range of $13.05 to $1
INDIANAPOLIS, April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into healing
Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program. Additional progress included positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH).Bus
INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly unites car
INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we
Citigroup resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,060.00
Deutsche Bank upgraded Eli Lilly from Hold to Buy and set a new price target of $1,025.00
DZ Bank downgraded Eli Lilly from Buy to Hold and set a new price target of $820.00
Morgan Stanley reiterated coverage of Eli Lilly with a rating of Overweight and set a new price target of $950.00 from $805.00 previously
Daiwa Securities downgraded Eli Lilly from Buy to Outperform and set a new price target of $610.00 from $660.00 previously
Deutsche Bank initiated coverage of Eli Lilly with a rating of Hold and set a new price target of $535.00
UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $710.00 from $612.00 previously
Jefferies upgraded Eli Lilly from Hold to Buy and set a new price target of $615.00 from $408.00 previously
Citigroup reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $525.00 from $360.00 previously
HSBC Securities initiated coverage of Eli Lilly with a rating of Buy and set a new price target of $560.00
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat
For Immediate Release: September 23, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “FDA Issues New Guidance to Help Facilitate Availability of Naloxone to Prevent Opioid Overdoses and Reduce Death,” by Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health, Center f
For Immediate Release: June 13, 2022 Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific locati
INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage
INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024. Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan and dean of the Medical School, and he plans to retire on June 30, 2025. Following retirement from these leadership roles, Dr. Runge will remain on the Medical School faculty as a prof
INDIANAPOLIS, June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024. Seymour currently serves as the chief quality officer for Bristol Myers Squibb and succeeds Johna Norton, whose retirement after 34 years of service was announced earlier this year. "As we expand global capacity to meet demand and support pipeline growth, we remain committed to ensuring our medicines are produced to the highest quality standards," said David A. Ricks, Lilly's chair and CEO. "With more than 25 years of experience and a proven
INDIANAPOLIS, May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer. "Throughout his distinguished career, Alonzo has been a steadfast advocate for our company, providing strategic guidance to our global product development teams and major geographies worldwide," said David A. Ricks, Lilly's
INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity. "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at Lilly. "Through his deep financial knowledge and understanding of the business, industry and stakeholders, Phil has played a key leadership role in the company and is well recognized for his commitment to Lilly's purpose and the patients we serve. Additionally, he is known for his pass
INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024. She will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is actively underway for her successor. "Johna's career has been built on her commitment to ensuring that our medicines are produced with the highest quality standards. By ensuring our company, manufacturing sites, production lines, team members and collaborators share this commitment, she has h
- Stephen Fry to retire at the end of 2022 - Eric Dozier named Senior Vice President, Human Resources and Diversity - Winselow Tucker to join Lilly as Senior Vice President and Chief Commercial Officer for Loxo@Lilly INDIANAPOLIS, Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for Loxo@Lilly. After more than 35 years at Lilly, Stephen Fry, senior vice president, human resources and diversity, will retire at the end of 2022. Commenting on Fry's retirement, David A. Ricks, Lilly chair and CEO, said, "Steve has left a positive a
INDIANAPOLIS, April 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced financial results for the first quarter of 2021. $ in millions, except per share data First Quarter % 2021 2020 Change Revenue $ 6,805.6 $ 5,859.8 16% Net Income – Reported 1,355.3 1,456.5 (7)% EPS – Reported 1.49 1.60 (7)% Net Income – Non-GAAP 1,701.9 1,471.1 16% EPS – Non-GAAP 1.87 1.61 16% Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recog
INDIANAPOLIS, Feb. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms. Ashkenazi, who most recently served in the role of senior vice president, controller and chief financial officer of Lilly Research Laboratories, succeeds Josh Smiley, who has resigned as senior vice president and chief financial officer and will be leaving the company. Lilly was recently made aware of allegations of an inappropriate personal relationship between Mr. Smiley and an employee. Lilly immediately engaged external counsel to conduct a thorough, independent investigation. That investigation rev
INDIANAPOLIS, Jan. 14, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021. As a member of Lilly's board, she will serve on both the Audit Committee and the Ethics and Compliance Committee. Ms. Sulzberger is a strategic advisor to Two Sigma Impact, a private equity firm that combines active, principled ownership and data science, with the goal of achieving superior returns and positive social outcomes. Prior to joining Two Sigma Impact, Ms. Sulzberger was a general partner of private equity fund Rustic Canyon/Fontis Partners L.P. for 13 years. Ms. Sulzberger has previously served as